The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...
British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
The cancer portfolio also put in a buoyant ... climbed 41 per cent to £101 million. The latter product will of course not have an impact on GSK's future growth, as it is one of the oncology ...
Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...
GSK plc (NYSE:GSK) develops and markets a wide range of healthcare products, including vaccines, specialty medicines, and general medicines. Its portfolio includes prescription drugs, over-the ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...
Cruz announces that investors with losses related to GSK plc. ("GSK" or the "Company") (NYSE: GSK) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO ...
Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against GSK plc. ("GSK" or the "Company") (NYSE: GSK). IF YOU ARE AN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback